APA (7th ed.) Citation

S, S., A, B., B, M., S, J., S, V., A, P., . . . E, M. (2021). Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium. Frontiers in pharmacology, 12, 628434. https://doi.org/10.3389/fphar.2021.628434

Chicago Style (17th ed.) Citation

S, Simoens, Bento-Abreu A, Merckx B, Joubert S, Vermeersch S, Pavelyev A, Varga S, and Morais E. "Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium." Frontiers in Pharmacology 12 (2021): 628434. https://doi.org/10.3389/fphar.2021.628434.

MLA (9th ed.) Citation

S, Simoens, et al. "Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium." Frontiers in Pharmacology, vol. 12, 2021, p. 628434, https://doi.org/10.3389/fphar.2021.628434.